Biopsy of breast cancer metastases: patient characteristics and survival

[1]  Maria Adler,et al.  Multivariable Analysis A Practical Guide For Clinicians , 2016 .

[2]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[3]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Cristofanilli,et al.  Molecular characterization and targeted therapeutic approaches in breast cancer , 2015, Breast Cancer Research.

[5]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[6]  M. Fernö,et al.  Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Somerfield,et al.  Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of oncology practice / American Society of Clinical Oncology.

[8]  J. Bergh,et al.  Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology. , 2014, European journal of cancer.

[9]  M. Özgüroğlu,et al.  Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions , 2014, Oncology Research and Treatment.

[10]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Yan-Fang Xie,et al.  Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients , 2014, Medical Oncology.

[12]  A. Goldhirsch,et al.  A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. , 2014, European journal of cancer.

[13]  Cheng Xu,et al.  The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer , 2014, World Journal of Surgical Oncology.

[14]  Luca Fumagalli,et al.  Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives , 2014, Breast Cancer Research.

[15]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[16]  X. Pivot,et al.  Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. , 2013, The oncologist.

[17]  F. André,et al.  Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. , 2012, Critical reviews in oncology/hematology.

[18]  A. Thompson,et al.  Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.

[19]  Mark Clemons,et al.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[21]  L. Pusztai,et al.  Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. , 2010, The oncologist.

[22]  Pieter Wesseling,et al.  Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.

[23]  M. Kleinpeter.  Multivariable Analysis: A Practical Guide for Clinicians, 2nd edition edited by Katz, M. H. Study Design and Statistical Analysis: A Practical Guide for Clinicians edited by Katz, M. H. , 2007 .

[24]  S. Devesa,et al.  Probabilities of death from breast cancer and other causes among female breast cancer patients. , 2004, Journal of the National Cancer Institute.

[25]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[26]  R. Elledge,et al.  Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[28]  M. Brennan,et al.  The variability of estrogen receptors in metastatic breast cancer. , 1979, American journal of surgery.